Drug intelligence / Profile preview

AL101-AMD

Development stage: Preclinical
Lead developer: AngioLab
Modality: Small Molecules
Administration: Oral

Overview

AL101-AMD is an orally available treatment for age-related macular degeneration (AMD) developed by AngioLab. It contains the active ingredient ALS-L1023, which inhibits multiple angiogenic factors including VEGF, bFGF, PDGF, and MMPs. Unlike competitor treatments that require injection, AL101-AMD is administered orally and is designed for long-term treatment without side effects.

Targets

PDGF (Platelet-derived Growth Factor family)FGF2MMP12 (Macrophage Metalloelastase)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on AL101-AMD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL101-AMD.

Explore the full profile